What is MicroSynbiotiX?
Headquartered in Cork City, Ireland, MicroSynbiotiX is a biotechnology enterprise specializing in the intersection of algal genomics and molecular biology. The company has developed a sophisticated technology solution designed to mitigate the reliance on antibiotics in aquaculture. By engineering microalgae to function as an oral delivery vehicle for therapeutic proteins and vaccines, the firm addresses the dual challenges of high fish mortality rates and the economic burden of traditional disease management. This approach not only enhances the sustainability of fish stocks but also provides a cost-effective, user-friendly alternative to conventional injection-based vaccination methods, thereby strengthening global food security protocols.
How much funding has MicroSynbiotiX raised?
MicroSynbiotiX has raised a total of $1.2M across 1 funding round:
Angel/Seed
$1.2M
Angel/Seed (2017): $1.2M, investors not publicly disclosed
Key Investors in MicroSynbiotiX
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for MicroSynbiotiX?
Following this major strategic investment, MicroSynbiotiX is expected to accelerate its research and development pipeline, focusing on the optimization of its oral vaccine delivery platform. The company will likely prioritize expanding its operational footprint to meet the growing demand for sustainable aquaculture solutions. By leveraging its expertise in algal genomics, the firm aims to establish new industry standards for disease prevention, effectively reducing the environmental impact of industrial fish farming while simultaneously improving the economic viability of large-scale operations. Future milestones will likely involve strategic partnerships with global aquaculture producers to integrate these therapeutic solutions into standard farm management practices.
See full MicroSynbiotiX company page
